Anavex Life Sciences Corp.

AVXL · NASDAQ
Analyze with AI
9/30/2025
9/30/2024
9/30/2023
9/30/2022
Operating Activities
Net Income-$46,377-$43,002-$47,505-$47,978
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$11,549$9,438$16,370$18,379
Change in WC$0$2,752$2,505$5,361
Other Non-Cash-$4,216$0$845$0
Operating Cash Flow-$39,044-$30,812-$27,785-$24,238
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow$0$0$0$0
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$1,493$11,284$27,875$20,985
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$9,434$691$1,776$303
Financing Cash Flow$9,434$11,975$29,651$21,288
Forex Effect$0$0$0$0
Net Chg. in Cash-$29,610-$18,837$1,866-$2,950
Supplemental Information
Beg. Cash$132,187$151,024$149,158$152,108
End Cash$102,577$132,187$151,024$149,158
Free Cash Flow-$39,044-$30,812-$27,785-$24,238